Literature DB >> 30973543

Current US Guidelines for Prescribing HIV Pre-exposure Prophylaxis (PrEP) Disqualify Many Women Who Are at Risk and Motivated to Use PrEP.

Sarah K Calabrese1,2, Tiara C Willie2,3,4, Rachel W Galvao1,5, Mehrit Tekeste1, John F Dovidio2,6,7, Cara B Safon7,8, Oni Blackstock2,9, Tamara Taggart2,10, Clair Kaplan11, Abigail Caldwell11, Trace S Kershaw2,7.   

Abstract

BACKGROUND: US Centers for Disease Control and Prevention clinical guidelines for HIV pre-exposure prophylaxis (PrEP) are widely used to assess patients' PrEP eligibility. The guidelines include 2 versions of criteria-guidance summary criteria and recommended indications criteria-that diverge in a potentially critical way for heterosexually active women: Both require women's knowledge of their own risk behavior, but the recommended indications also require women's knowledge of their partners' HIV risk or recognition of a potentially asymptomatic sexually transmitted infection. This study examined women's PrEP eligibility according to these 2 different versions of criteria across risk and motivation categories. SETTING/
METHODS: HIV-negative women (n = 679) recently engaged in care at Connecticut Planned Parenthood centers were surveyed online in 2017. The survey assessed PrEP eligibility by both versions of Centers for Disease Control and Prevention criteria, HIV risk indicators, PrEP motivation indicators, and sociodemographic characteristics.
RESULTS: Participants were mostly non-Hispanic white (33.9%) or black (35.8%) and had low income (<$30,000/year; 58.3%). Overall, 82.3% were eligible for PrEP by guidance summary criteria vs. 1.5% by recommended indications criteria. Women disqualified by recommended indications criteria included those reporting condomless sex with HIV-positive or serostatus-unknown male partners (n = 27, 11.1% eligible); 1 or more recent sexually transmitted infection(s) (n = 53, 3.8% eligible); multiple sex partners (n = 168, 3.0% eligible); intended PrEP use (n = 211, 2.8% eligible); and high self-perceived risk (n = 5, 0.0% eligible).
CONCLUSION: Current guidelines disqualify many women who could benefit from PrEP and may lead to discrepant assessments of eligibility. Guideline reform is needed to improve clarity and increase women's PrEP access and consequent HIV protection.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30973543      PMCID: PMC6594908          DOI: 10.1097/QAI.0000000000002042

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  37 in total

1.  Hidden in Plain Sight: Identifying Women Living in the United States Who Could Benefit From HIV Preexposure Prophylaxis.

Authors:  B O Ojikutu; K H Mayer
Journal:  J Infect Dis       Date:  2020-10-01       Impact factor: 5.226

2.  US Guideline Criteria for Human Immunodeficiency Virus Preexposure Prophylaxis: Clinical Considerations and Caveats.

Authors:  Sarah K Calabrese; Douglas S Krakower; Tiara C Willie; Trace S Kershaw; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2019-08-16       Impact factor: 9.079

3.  Contraception as a Potential Gateway to Pre-Exposure Prophylaxis: US Women's Pre-Exposure Prophylaxis Modality Preferences Align with Their Birth Control Practices.

Authors:  Sarah K Calabrese; Rachel W Galvao; John F Dovidio; Tiara C Willie; Cara B Safon; Clair Kaplan; Abigail Caldwell; Oni Blackstock; Nicole J Phillips; Trace S Kershaw
Journal:  AIDS Patient Care STDS       Date:  2020-03       Impact factor: 5.078

4.  Models of HIV Pre-Exposure Prophylaxis Care Used in Title X Family Planning Clinics in the Southern U.S.

Authors:  Kaitlin N Piper; Cam Escoffery; Jessica M Sales; Anandi N Sheth
Journal:  J Adolesc Health       Date:  2020-11-05       Impact factor: 5.012

5.  Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.

Authors:  Jill Blumenthal; Sonia Jain; Feng He; K Rivet Amico; Ryan Kofron; Eric Ellorin; Jamila K Stockman; Christina Psaros; Gifty M Ntim; Karen Chow; Peter L Anderson; Richard Haubrich; Katya Corado; David J Moore; Sheldon Morris; Raphael J Landovitz
Journal:  Clin Infect Dis       Date:  2021-10-05       Impact factor: 9.079

6.  Evaluation of an Electronic Algorithm for Identifying Cisgender Female Pre-Exposure Prophylaxis Candidates.

Authors:  Jessica P Ridgway; Eleanor E Friedman; Alvie Bender; Jessica Schmitt; Michael Cronin; Rayna N Brown; Amy K Johnson; Lisa R Hirschhorn
Journal:  AIDS Patient Care STDS       Date:  2021-01       Impact factor: 5.078

Review 7.  Recommendations for Increasing Physician Provision of Pre-Exposure Prophylaxis: Implications for Medical Student Training.

Authors:  Robert L Cooper; Paul D Juarez; Matthew C Morris; Aramandla Ramesh; Ryan Edgerton; Lauren L Brown; Leandro Mena; Samuel A MacMaster; Shavonne Collins; Patricia Matthews- Juarez; Mohammad Tabatabai; Katherine Y Brown; Michael J Paul; Wansoo Im; Thomas A Arcury; Marybeth Shinn
Journal:  Inquiry       Date:  2021 Jan-Dec       Impact factor: 1.730

8.  Racial and ethnic differences in women's HIV risk and attitudes towards pre-exposure prophylaxis (PrEP) in the context of the substance use, violence, and depression syndemic.

Authors:  Tiara C Willie; Trace S Kershaw; Oni Blackstock; Rachel W Galvao; Cara B Safon; Mehrit Tekeste; Damon F Ogburn; Brittany Wilbourn; Djordje Modrakovic; Tamara Taggart; Clair Kaplan; Abigail Caldwell; Sarah K Calabrese
Journal:  AIDS Care       Date:  2020-05-14

9.  Birth Control Sabotage as a Correlate of Women's Sexual Health Risk: An Exploratory Study.

Authors:  Tiara C Willie; Kamila A Alexander; Amy Caplon; Trace S Kershaw; Cara B Safon; Rachel W Galvao; Clair Kaplan; Abigail Caldwell; Sarah K Calabrese
Journal:  Womens Health Issues       Date:  2020-11-18

10.  No Longer the Exception, but the Standard: Integrating Trauma-Informed Policy and Pre-exposure Prophylaxis Implementation for Women.

Authors:  Tiara C Willie; Kamila A Alexander; Trace Kershaw; Jacquelyn C Campbell; Jamila K Stockman
Journal:  Womens Health Issues       Date:  2021-06-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.